

Hyperlipidemia Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

<https://marketpublishers.com/r/H02933AD93FBEN.html>

Date: May 2025

Pages: 86

Price: US\$ 3,200.00 (Single User License)

ID: H02933AD93FBEN

Abstracts

Hyperlipidemia Drugs Market Summary

Introduction and Market Overview

Hyperlipidemia drugs, including statins, PCSK9 inhibitors, and fibric acid derivatives, manage high cholesterol, a key risk factor for cardiovascular disease (CVD), which caused 17.9 million deaths in 2019. The market is driven by high CVD prevalence (33% of adults globally have high cholesterol), an aging population (40% prevalence in those over 60), and lifestyle factors like obesity (424 million obese adults). Novel therapies like inclisiran and bempedoic acid, with 20% improved adherence, and accelerated FDA approvals (15% faster market entry) boost growth. The global hyperlipidemia drugs market is estimated at USD 800-1,300 million in 2025, with a CAGR of 4%-8% through 2030.

Regional Market Trends

North America: The U.S. leads with high CVD rates and PCSK9 inhibitor adoption, while Canada focuses on preventive care.

Europe: Germany, France, and the UK drive growth with robust lipid-lowering programs.

Asia Pacific: China and India see rising demand due to lifestyle changes, with Japan emphasizing novel therapies.

Rest of the World: Brazil expands CVD management, while the Middle East addresses metabolic disorders.

Distribution Channel Analysis

Hospital Pharmacies: Expected growth of 4.5%-8.5%, driven by PCSK9 inhibitors. Trends focus on specialized care.

Online Pharmacies: Projected growth of 5.0%-9.0%, linked to patient convenience. Advances emphasize digital prescriptions.

Retail Pharmacies: Anticipated growth of 4.0%-8.0%, covering statins. Trends highlight community access.

Type Analysis

Statins: Expected growth of 3.5%-7.5%, valued for efficacy. Trends focus on generic formulations.

Bile Acid Sequestrants: Projected growth of 3.0%-7.0%, used in niche cases. Advances emphasize combination therapies.

Cholesterol Absorption Inhibitors: Anticipated growth of 3.8%-7.8%, suited for adjunct therapy. Trends highlight oral agents.

Fibric Acid Derivatives: Expected growth of 3.2%-7.2%, for triglyceride management. Developments prioritize safety profiles.

PCSK9 Inhibitors: Expected growth of 5.5%-9.5%, favored for high-risk patients. Trends focus on siRNA therapies.

Combination: Expected growth of 4.2%-8.2%, for comprehensive management. Trends highlight fixed-dose combinations.

Miscellaneous: Expected growth of 3.0%-7.0%, covering novel drugs. Developments prioritize non-statin options.

Key Market Players

Pfizer: Offers statins for cholesterol management.

AstraZeneca: Develops combination therapies.

Amgen: Provides PCSK9 inhibitors.

Sanofi: Focuses on novel lipid-lowering drugs.

Merck: Supplies cholesterol absorption inhibitors.

Porter's Five Forces Analysis

Threat of New Entrants: Moderate, due to high R&D costs, but generics lower barriers.

Threat of Substitutes: Moderate, with lifestyle interventions competing, but drugs are primary for severe cases.

Bargaining Power of Buyers: High, as generics increase price competition.

Bargaining Power of Suppliers: Low, with multiple API providers.

Competitive Rivalry: High, with players competing on efficacy and cost.

Market Opportunities and Challenges

Opportunities:

Addressing CVD, causing 17.9 million deaths annually.

Leveraging an aging population, with 40% cholesterol prevalence.

Managing obesity, affecting 424 million adults.

Utilizing novel therapies, improving adherence by 20%.

Benefiting from accelerated FDA approvals.

Expanding preventive care in emerging markets.

Challenges:

Price erosion due to generics.

Competition from lifestyle interventions.

Regulatory delays for novel drugs.

High costs of PCSK9 inhibitors limiting access.

Patient adherence issues with long-term therapies.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis

6.2 Hyperlipidemia Drug Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News

7.2 Merger and Acquisition

- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST HYPERLIPIDEMIA DRUG MARKET IN NORTH AMERICA (2020-2030)

- 8.1 Hyperlipidemia Drug Market Size
- 8.2 Hyperlipidemia Drug Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Hyperlipidemia Drug Market Size by Type
- 8.5 Key Countries Analysis
 - 8.5.1 United States
 - 8.5.2 Canada
 - 8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST HYPERLIPIDEMIA DRUG MARKET IN SOUTH AMERICA (2020-2030)

- 9.1 Hyperlipidemia Drug Market Size
- 9.2 Hyperlipidemia Drug Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Hyperlipidemia Drug Market Size by Type
- 9.5 Key Countries Analysis
 - 9.5.1 Brazil
 - 9.5.2 Argentina
 - 9.5.3 Chile
 - 9.5.4 Peru

CHAPTER 10 HISTORICAL AND FORECAST HYPERLIPIDEMIA DRUG MARKET IN ASIA & PACIFIC (2020-2030)

- 10.1 Hyperlipidemia Drug Market Size
- 10.2 Hyperlipidemia Drug Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Hyperlipidemia Drug Market Size by Type
- 10.5 Key Countries Analysis
 - 10.5.1 China
 - 10.5.2 India
 - 10.5.3 Japan

- 10.5.4 South Korea
- 10.5.5 Southeast Asia
- 10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST HYPERLIPIDEMIA DRUG MARKET IN EUROPE (2020-2030)

- 11.1 Hyperlipidemia Drug Market Size
- 11.2 Hyperlipidemia Drug Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Hyperlipidemia Drug Market Size by Type
- 11.5 Key Countries Analysis
 - 11.5.1 Germany
 - 11.5.2 France
 - 11.5.3 United Kingdom
 - 11.5.4 Italy
 - 11.5.5 Spain
 - 11.5.6 Belgium
 - 11.5.7 Netherlands
 - 11.5.8 Austria
 - 11.5.9 Poland
 - 11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST HYPERLIPIDEMIA DRUG MARKET IN MEA (2020-2030)

- 12.1 Hyperlipidemia Drug Market Size
- 12.2 Hyperlipidemia Drug Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Hyperlipidemia Drug Market Size by Type
- 12.5 Key Countries Analysis
 - 12.5.1 Egypt
 - 12.5.2 Israel
 - 12.5.3 South Africa
 - 12.5.4 Gulf Cooperation Council Countries
 - 12.5.5 Turkey

CHAPTER 13 SUMMARY FOR GLOBAL HYPERLIPIDEMIA DRUG MARKET (2020-2025)

- 13.1 Hyperlipidemia Drug Market Size
- 13.2 Hyperlipidemia Drug Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Hyperlipidemia Drug Market Size by Type

CHAPTER 14 GLOBAL HYPERLIPIDEMIA DRUG MARKET FORECAST (2025-2030)

- 14.1 Hyperlipidemia Drug Market Size Forecast
- 14.2 Hyperlipidemia Drug Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Hyperlipidemia Drug Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

15.1 Pfizer

- 15.1.1 Company Profile
- 15.1.2 Main Business and Hyperlipidemia Drug Information
- 15.1.3 SWOT Analysis of Pfizer
- 15.1.4 Pfizer Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)

15.2 AstraZeneca

- 15.2.1 Company Profile
- 15.2.2 Main Business and Hyperlipidemia Drug Information
- 15.2.3 SWOT Analysis of AstraZeneca
- 15.2.4 AstraZeneca Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)

15.3 Amgen

- 15.3.1 Company Profile
- 15.3.2 Main Business and Hyperlipidemia Drug Information
- 15.3.3 SWOT Analysis of Amgen
- 15.3.4 Amgen Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)

15.4 Sanofi

- 15.4.1 Company Profile
- 15.4.2 Main Business and Hyperlipidemia Drug Information
- 15.4.3 SWOT Analysis of Sanofi
- 15.4.4 Sanofi Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)

15.5 Merck

15.5.1 Company Profile

15.5.2 Main Business and Hyperlipidemia Drug Information

15.5.3 SWOT Analysis of Merck

15.5.4 Merck Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)

15.6 Viatris

15.6.1 Company Profile

15.6.2 Main Business and Hyperlipidemia Drug Information

15.6.3 SWOT Analysis of Viatris

15.6.4 Viatris Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

Tables and Figures

Table Abbreviation and Acronyms

Table Research Scope of Hyperlipidemia Drug Report

Table Data Sources of Hyperlipidemia Drug Report

Table Major Assumptions of Hyperlipidemia Drug Report

Figure Market Size Estimated Method

Figure Major Forecasting Factors

Figure Hyperlipidemia Drug Picture

Table Hyperlipidemia Drug Classification

Table Hyperlipidemia Drug Applications

Table Drivers of Hyperlipidemia Drug Market

Table Restraints of Hyperlipidemia Drug Market

Table Opportunities of Hyperlipidemia Drug Market

Table Threats of Hyperlipidemia Drug Market

Table Covid-19 Impact For Hyperlipidemia Drug Market

Table Raw Materials Suppliers

Table Different Production Methods of Hyperlipidemia Drug

Table Cost Structure Analysis of Hyperlipidemia Drug

Table Key End Users

Table Latest News of Hyperlipidemia Drug Market

Table Merger and Acquisition

Table Planned/Future Project of Hyperlipidemia Drug Market

Table Policy of Hyperlipidemia Drug Market

Table 2020-2030 North America Hyperlipidemia Drug Market Size

Figure 2020-2030 North America Hyperlipidemia Drug Market Size and CAGR

Table 2020-2030 North America Hyperlipidemia Drug Market Size by Application

Table 2020-2025 North America Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 North America Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 North America Hyperlipidemia Drug Market Size by Type
Table 2020-2030 United States Hyperlipidemia Drug Market Size
Table 2020-2030 Canada Hyperlipidemia Drug Market Size
Table 2020-2030 Mexico Hyperlipidemia Drug Market Size
Table 2020-2030 South America Hyperlipidemia Drug Market Size
Figure 2020-2030 South America Hyperlipidemia Drug Market Size and CAGR
Table 2020-2030 South America Hyperlipidemia Drug Market Size by Application
Table 2020-2025 South America Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 South America Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 South America Hyperlipidemia Drug Market Size by Type
Table 2020-2030 Brazil Hyperlipidemia Drug Market Size
Table 2020-2030 Argentina Hyperlipidemia Drug Market Size
Table 2020-2030 Chile Hyperlipidemia Drug Market Size
Table 2020-2030 Peru Hyperlipidemia Drug Market Size
Table 2020-2030 Asia & Pacific Hyperlipidemia Drug Market Size
Figure 2020-2030 Asia & Pacific Hyperlipidemia Drug Market Size and CAGR
Table 2020-2030 Asia & Pacific Hyperlipidemia Drug Market Size by Application
Table 2020-2025 Asia & Pacific Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Hyperlipidemia Drug Market Size by Type
Table 2020-2030 China Hyperlipidemia Drug Market Size
Table 2020-2030 India Hyperlipidemia Drug Market Size
Table 2020-2030 Japan Hyperlipidemia Drug Market Size
Table 2020-2030 South Korea Hyperlipidemia Drug Market Size
Table 2020-2030 Southeast Asia Hyperlipidemia Drug Market Size
Table 2020-2030 Australia Hyperlipidemia Drug Market Size
Table 2020-2030 Europe Hyperlipidemia Drug Market Size
Figure 2020-2030 Europe Hyperlipidemia Drug Market Size and CAGR
Table 2020-2030 Europe Hyperlipidemia Drug Market Size by Application
Table 2020-2025 Europe Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 Europe Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 Europe Hyperlipidemia Drug Market Size by Type
Table 2020-2030 Germany Hyperlipidemia Drug Market Size
Table 2020-2030 France Hyperlipidemia Drug Market Size
Table 2020-2030 United Kingdom Hyperlipidemia Drug Market Size
Table 2020-2030 Italy Hyperlipidemia Drug Market Size
Table 2020-2030 Spain Hyperlipidemia Drug Market Size

Table 2020-2030 Belgium Hyperlipidemia Drug Market Size
Table 2020-2030 Netherlands Hyperlipidemia Drug Market Size
Table 2020-2030 Austria Hyperlipidemia Drug Market Size
Table 2020-2030 Poland Hyperlipidemia Drug Market Size
Table 2020-2030 Russia Hyperlipidemia Drug Market Size
Table 2020-2030 MEA Hyperlipidemia Drug Market Size
Figure 2020-2030 MEA Hyperlipidemia Drug Market Size and CAGR
Table 2020-2030 MEA Hyperlipidemia Drug Market Size by Application
Table 2020-2025 MEA Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 MEA Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 MEA Hyperlipidemia Drug Market Size by Type
Table 2020-2030 Egypt Hyperlipidemia Drug Market Size
Table 2020-2030 Israel Hyperlipidemia Drug Market Size
Table 2020-2030 South Africa Hyperlipidemia Drug Market Size
Table 2020-2030 Gulf Cooperation Council Countries Hyperlipidemia Drug Market Size
Table 2020-2030 Turkey Hyperlipidemia Drug Market Size
Table 2020-2025 Global Hyperlipidemia Drug Market Size by Region
Table 2020-2025 Global Hyperlipidemia Drug Market Size Share by Region
Table 2020-2025 Global Hyperlipidemia Drug Market Size by Application
Table 2020-2025 Global Hyperlipidemia Drug Market Share by Application
Table 2020-2025 Global Hyperlipidemia Drug Key Vendors Revenue
Figure 2020-2025 Global Hyperlipidemia Drug Market Size and Growth Rate
Table 2020-2025 Global Hyperlipidemia Drug Key Vendors Market Share
Table 2020-2025 Global Hyperlipidemia Drug Market Size by Type
Table 2020-2025 Global Hyperlipidemia Drug Market Share by Type
Table 2025-2030 Global Hyperlipidemia Drug Market Size by Region
Table 2025-2030 Global Hyperlipidemia Drug Market Size Share by Region
Table 2025-2030 Global Hyperlipidemia Drug Market Size by Application
Table 2025-2030 Global Hyperlipidemia Drug Market Share by Application
Table 2025-2030 Global Hyperlipidemia Drug Key Vendors Revenue
Figure 2025-2030 Global Hyperlipidemia Drug Market Size and Growth Rate
Table 2025-2030 Global Hyperlipidemia Drug Key Vendors Market Share
Table 2025-2030 Global Hyperlipidemia Drug Market Size by Type
Table 2025-2030 Hyperlipidemia Drug Global Market Share by Type

I would like to order

Product name: Hyperlipidemia Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Product link: <https://marketpublishers.com/r/H02933AD93FBEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H02933AD93FBEN.html>